BACKGROUND: Reports on long-term (≥10 years) effects of cancer vaccines are missing. Therefore, in 2002, we initiated a phase I/II trial in cutaneous melanoma patients to further explore the immunogenicity of our DC vaccine and to establish its long-term toxicity and clinical benefit after a planned 10-year followup. METHODS: Monocyte-derived DCs matured by TNFα, IL-1β, IL-6, and PGE2 and then loaded with 4 HLA class I and 6 class II-restricted tumor peptides were injected intradermally in high doses over 2 years. We performed serial immunomonitoring in all 53 evaluable patients. RESULTS: Vaccine-specific immune responses including high-affinity, IFNγ-producing CD4+ and lytic polyfunctional CD8+ T cells were de novo induced or boosted in most patients. Exposure of mature DCs to trimeric soluble CD40 ligand, unexpectedly, did not further enhance such immune responses, while keyhole limpet hemocyanin (KLH) pulsing to provide unspecific CD4+ help promoted CD8+ T cell responses - notably, their longevity. An unexpected 19% of nonresectable metastatic melanoma patients are still alive after 11 years, a survival rate similar to that observed in ipilimumab-treated patients and achieved without any major (>grade 2) toxicity. Survival correlated significantly with the development of intense vaccine injection site reactions, and with blood eosinophilia after the first series of vaccinations, suggesting that prolonged survival was a consequence of DC vaccination. CONCLUSIONS: Long-term survival in advanced melanoma patients undergoing DC vaccination is similar to ipilimumab-treated patients and occurs upon induction of tumor-specific T cells, blood eosinophilia, and strong vaccine injection site reactions occurring after the initial vaccinations. TRIAL REGISTRATION: ClinicalTrials.gov NCT00053391. FUNDING: European Community, Sixth Framework Programme (Cancerimmunotherapy LSHC-CT-2006-518234; DC-THERA LSHB-CT-2004-512074), and German Research Foundation (CRC 643, C1, Z2).
BACKGROUND: Reports on long-term (≥10 years) effects of cancer vaccines are missing. Therefore, in 2002, we initiated a phase I/II trial in cutaneous melanomapatients to further explore the immunogenicity of our DC vaccine and to establish its long-term toxicity and clinical benefit after a planned 10-year followup. METHODS: Monocyte-derived DCs matured by TNFα, IL-1β, IL-6, and PGE2 and then loaded with 4 HLA class I and 6 class II-restricted tumor peptides were injected intradermally in high doses over 2 years. We performed serial immunomonitoring in all 53 evaluable patients. RESULTS: Vaccine-specific immune responses including high-affinity, IFNγ-producing CD4+ and lytic polyfunctional CD8+ T cells were de novo induced or boosted in most patients. Exposure of mature DCs to trimeric soluble CD40 ligand, unexpectedly, did not further enhance such immune responses, while keyhole limpet hemocyanin (KLH) pulsing to provide unspecific CD4+ help promoted CD8+ T cell responses - notably, their longevity. An unexpected 19% of nonresectable metastatic melanomapatients are still alive after 11 years, a survival rate similar to that observed in ipilimumab-treated patients and achieved without any major (>grade 2) toxicity. Survival correlated significantly with the development of intense vaccine injection site reactions, and with blood eosinophilia after the first series of vaccinations, suggesting that prolonged survival was a consequence of DC vaccination. CONCLUSIONS: Long-term survival in advanced melanomapatients undergoing DC vaccination is similar to ipilimumab-treated patients and occurs upon induction of tumor-specific T cells, blood eosinophilia, and strong vaccine injection site reactions occurring after the initial vaccinations. TRIAL REGISTRATION: ClinicalTrials.gov NCT00053391. FUNDING: European Community, Sixth Framework Programme (Cancerimmunotherapy LSHC-CT-2006-518234; DC-THERA LSHB-CT-2004-512074), and German Research Foundation (CRC 643, C1, Z2).
Authors: Redas Trepiakas; Annika Berntsen; Sine Reker Hadrup; Jon Bjørn; Poul F Geertsen; Per Thor Straten; Mads H Andersen; Anders E Pedersen; Amir Soleimani; Torben Lorentzen; Julia S Johansen; Inge Marie Svane Journal: Cytotherapy Date: 2010-10 Impact factor: 5.414
Authors: Joseph W Fay; A Karolina Palucka; Sophie Paczesny; Madhav Dhodapkar; Dennis A Johnston; Susan Burkeholder; Hideki Ueno; Jacques Banchereau Journal: Cancer Immunol Immunother Date: 2005-12-06 Impact factor: 6.968
Authors: Geoffrey T Gibney; Ragini R Kudchadkar; Ronald C DeConti; Melissa S Thebeau; Maria P Czupryn; Leticia Tetteh; Cabell Eysmans; Allison Richards; Michael J Schell; Kate J Fisher; Christine E Horak; H David Inzunza; Bin Yu; Alberto J Martinez; Ibrahim Younos; Jeffrey S Weber Journal: Clin Cancer Res Date: 2014-12-18 Impact factor: 12.531
Authors: Sjoerd H van der Burg; Ramon Arens; Ferry Ossendorp; Thorbald van Hall; Cornelis J M Melief Journal: Nat Rev Cancer Date: 2016-03-11 Impact factor: 60.716
Authors: Robert O Dillman; Senthamil R Selvan; Patric M Schiltz; Edward F McClay; Neil M Barth; Carol DePriest; Cristina de Leon; Cheryl Mayorga; Andrew N Cornforth; Kanoe Allen Journal: Cancer Biother Radiopharm Date: 2009-06 Impact factor: 3.099
Authors: James L Gulley; Peter Mulders; Peter Albers; Jacques Banchereau; Michel Bolla; Klaus Pantel; Thomas Powles Journal: Oncoimmunology Date: 2015-12-10 Impact factor: 8.110
Authors: Stephen T Ferris; Ray A Ohara; Feiya Ou; Renee Wu; Xiao Huang; Sunkyung Kim; Jing Chen; Tian-Tian Liu; Robert D Schreiber; Theresa L Murphy; Kenneth M Murphy Journal: Cancer Immunol Res Date: 2022-08-03 Impact factor: 12.020
Authors: Anthony L Cunningham; Thomas C Heineman; Himal Lal; Olivier Godeaux; Roman Chlibek; Shinn-Jang Hwang; Janet E McElhaney; Timo Vesikari; Charles Andrews; Won Suk Choi; Meral Esen; Hideyuki Ikematsu; Martina Kovac Choma; Karlis Pauksens; Stéphanie Ravault; Bruno Salaun; Tino F Schwarz; Jan Smetana; Carline Vanden Abeele; Peter Van den Steen; Ilse Vastiau; Lily Yin Weckx; Myron J Levin Journal: J Infect Dis Date: 2018-05-05 Impact factor: 5.226